Drug insight: Abatacept for the treatment of rheumatoid arthritis

Nature Clinical Practice Rheumatology

Volumn 2, Issue 12, 2006, Pages 654-660

  Ruderman, Eric M ^a   Pope, Richard M ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABATACEPT; ADALIMUMAB; B7 ANTIGEN; CD28 ANTIGEN; CD86 ANTIGEN; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; INFLIXIMAB; METHOTREXATE; PLACEBO; PREDNISONE; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; TUMOR NECROSIS FACTOR ANTIBODY;

ANTIGEN BINDING; ANTIINFLAMMATORY ACTIVITY; ANXIETY DISORDER; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CRYPTOCOCCOSIS; DISEASE ACTIVITY; DRUG CONTRAINDICATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG TARGETING; DRUG WITHDRAWAL; HUMAN; INFECTION; LUNG INFECTION; MONOTHERAPY; OPPORTUNISTIC INFECTION; PRIORITY JOURNAL; REMISSION; REVIEW; RHEUMATOID ARTHRITIS; SIGNAL TRANSDUCTION; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; TREATMENT FAILURE; TREATMENT OUTCOME;

ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; CLINICAL TRIALS, PHASE II; CLINICAL TRIALS, PHASE III; HUMANS; IMMUNOCONJUGATES; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 33751546353     PISSN: 17458382     EISSN: 17458390     Source Type: Journal    
DOI: 10.1038/ncprheum0345     Document Type: Review

References (25)

1. Pope RM and Perlman H (1999) Rheumatoid arthritis: Molecular pathogenesis. In Molecular Rheumatology, 325-361 (Ed. Dolgert P) New Jersey: Humana Press
2. Firestein GS (2003) Evolving concepts of rheumatoid arthritis. Nature 423: 356-361
3. Keystone EC (2003) Abandoned therapies and unpublished trials in rheumatoid arthritis. Curr Opin Rheumatol 15: 253-258
4. Moreland LW et al. (2002) Costimulatory blockade in patients with rheumatoid arthritis: A pilot, dosefinding, double-blind, placebo-controlled clinical trial evaluating CTLA-4Ig and LEA29Y eighty-five days after the first infusion. Arthritis Rheum 46: 1470-1479
5. Kremer JM et al. (2003) Treatment of rheumatoid arthritis by selective inhibition of T-cell activation with fusion protein CTLA4Ig. N Engl J Med 349: 1907-1915
6. Kremer JM et al. (2005) Treatment of rheumatoid arthritis with the selective costimulation modulator abatacept: Twelve-month results of a phase iib, double-blind, randomized, placebo-controlled trial. Arthritis Rheum 52: 2263-2271
7. Genovese MC et al. (2005) Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition. N Engl J Med 353: 1114-1123
8. Kremer JM et al. (2006) Effects of abatacept in patients with methotrexate-resistant active rheumatoid arthritis. Ann Intern Med 144: 865-876
9. Bluestone JA et al. (2006) CTLA4Ig: Bridging the basic immunology with clinical application. Immunity 24: 233-238
10. Salomon B et al. (2000) B7/CD28 costimulation is essential for the homeostasis of the CD4+CD25+ immunoregulatory T cells that control autoimmune diabetes. Immunity 12: 431-440
11. Linsley PS et al. (1991) CTLA-4 is a second receptor for the B cell activation antigen B7. J Exp Med 174: 561-569
12. Walunas TL et al. (1996) CTLA-4 ligation blocks CD28-dependent T cell activation. J Exp Med 183: 2541-2550
13. Karandikar NJ et al. (1996) CTLA-4: A negative regulator of autoimmune disease. J Exp Med 184: 783-788
14. Walunas TL and Bluestone JA. (1998) CTLA-4 regulates tolerance induction and T cell differentiation in vivo. J Immunol 160: 3855-3860
15. Verwilghen J et al. (1994) Expression of functional B7 and CTLA4 on rheumatoid synovial T cells. J Immunol 153: 1378-1385
16. Bluestone JA (2005) Regulatory T-cell therapy: Is it ready for the clinic? Nat Rev Immunol 5: 343-349
17. Bluestone JA and Tang Q (2005) How do CD4+CD25+ regulatory T cells control autoimmunity? Curr Opin Immunol 17: 638-642
18. Tang Q et al. (2003) Cutting edge: CD28 controls peripheral homeostasis of CD4+CD25+ regulatory T cells. J Immunol 171: 3348-3352
19. Grohmann U et al. (2002) CTLA-4-Ig regulates tryptophan catabolism in vivo. Nat Immunol 3: 1097-1101
20. Weinblatt M et al. (2006) Selective co-stimulation modulation using abatacept in patients with active rheumatoid arthritis while receiving etanercept: A randomized clinical trial. Ann Rheum Dis [doi:10.1136/ ard.2006.055111]
21. Kremer J et al. (2004) Sustained clinical efficacy demonstrated by the selective co-stimulation modulator abatacept (CTLA4Ig) in combination with methotrexate at 2 years in rheumatoid arthritis patients with an inadequate response to methotrexate. Arthritis Rheum 50 (Suppl): S183
22. Dougados M et al. (2004) Sustained remission and major clinical response at 2 years shown with abatacept (CTLA4Ig) in combination with methotrexate in rheumatoid arthritis patients with an inadequate response to methotrexate. Arthritis Rheum 50 (Suppl): S185
23. Moreland L et al. (2004) Abatacept (CTLA4Ig) in combination with methotrexate for the treatment of rheumatoid arthritis: Favorable safety and tolerability profile sustained over 2 years. Arthritis Rheum 50 (Suppl): S563
24. Weinblatt M et al. (2006) Safety of the selective costimulation modulator abatacept in rheumatoid arthritis patients receiving background biologic and nonbiologic disease-modifying antirheumatic drugs: A one-year randomized, placebo-controlled study. Arthritis Rheum 54: 2807-2816
25. Genovese MC et al. (2004) Combination therapy with etanercept and anakinra in the treatment of patients with rheumatoid arthritis who have been treated unsuccessfully with methotrexate. Arthritis Rheum 50: 1412-1419